CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Price Slipped -0.74% to $71.08

Wolfe Research raised the price target for the CRISPR Therapeutics AG (NASDAQ:CRSP) stock to “a Peer perform”. The rating was released on February 15, 2024, according to finviz. The stock was initiated by Mizuho, who disclosed in a research note on September 27, 2023, to Buy and set the price objective to $82. Historical Earnings […]

Where are Investors’ Sentiments? CRISPR Therapeutics AG (CRSP) Stock

Wolfe Research raised the price target for the CRISPR Therapeutics AG (NASDAQ:CRSP) stock to “a Peer perform”. The rating was released on February 15, 2024, according to finviz. The stock was initiated by Mizuho, who disclosed in a research note on September 27, 2023, to Buy and set the price objective to $82. Historical Earnings […]

What is CRISPR Therapeutics AG’s (CRSP) Stock Real Technical Picture?

Wolfe Research raised the price target for the CRISPR Therapeutics AG (NASDAQ:CRSP) stock to “a Peer perform”. The rating was released on February 15, 2024, according to finviz. The stock was initiated by Mizuho, who disclosed in a research note on September 27, 2023, to Buy and set the price objective to $82. The latest […]

Top-line Growth is Likely to Be Driven by CRISPR Therapeutics AG (CRSP) Stock

Wolfe Research raised the price target for the CRISPR Therapeutics AG (NASDAQ:CRSP) stock to “a Peer perform”. The rating was released on February 15, 2024, according to finviz. The stock was initiated by Mizuho, who disclosed in a research note on September 27, 2023, to Buy and set the price objective to $82. Historical Earnings […]

Why CRISPR Therapeutics AG (NASDAQ:CRSP) Stock climbed 10.94% in Last Three Months?

Wolfe Research raised the price target for the CRISPR Therapeutics AG (NASDAQ:CRSP) stock to “a Peer perform”. The rating was released on February 15, 2024, according to finviz. The stock was initiated by Mizuho, who disclosed in a research note on September 27, 2023, to Buy and set the price objective to $82. Historical Earnings […]

CRISPR Therapeutics AG (CRSP) Stock is poised for a successful quarter

Wolfe Research raised the price target for the CRISPR Therapeutics AG (NASDAQ:CRSP) stock to “a Peer perform”. The rating was released on February 15, 2024, according to finviz. The stock was initiated by Mizuho, who disclosed in a research note on September 27, 2023, to Buy and set the price objective to $82. Historical Earnings […]

CRISPR Therapeutics AG (CRSP) Stock Still Strong Despite Competition

Wolfe Research raised the price target for the CRISPR Therapeutics AG (NASDAQ:CRSP) stock to “a Peer perform”. The rating was released on February 15, 2024, according to finviz. The stock was initiated by Mizuho, who disclosed in a research note on September 27, 2023, to Buy and set the price objective to $82. Historical Earnings […]

The future of CRISPR Therapeutics AG (CRSP) Stock is still in tatters?

Wolfe Research raised the price target for the CRISPR Therapeutics AG (NASDAQ:CRSP) stock to “a Peer perform”. The rating was released on February 15, 2024, according to finviz. The stock was initiated by Mizuho, who disclosed in a research note on September 27, 2023, to Buy and set the price objective to $82. Historical Earnings […]

A Real Picture of CRISPR Therapeutics AG (CRSP) Stock: The Fundamentals

Wolfe Research raised the price target for the CRISPR Therapeutics AG (NASDAQ:CRSP) stock to “a Peer perform”. The rating was released on February 15, 2024, according to finviz. The stock was initiated by Mizuho, who disclosed in a research note on September 27, 2023, to Buy and set the price objective to $82. Historical Earnings […]

CRISPR Therapeutics AG (CRSP) Stock Has More Upside Than Fundamentals Suggest

TD Cowen raised the price target for the CRISPR Therapeutics AG (NASDAQ:CRSP) stock from “a Market perform” to “an Underperform”. The rating was released on December 11, 2023, according to finviz. Historical Earnings Surprises and Revenue Forecasts Profit is the most critical financial performance measure. Every investor in a business is looking forward to the […]